Home
Stampa
 
Aula Magna
Aula 211
Aula 201
Aula Malliani
Aula Crociera
Aula 113
10.00 - 13.00
Apertura Segreteria e Registrazione
13.00 - 13.30
13.30 - 16.00
16.00 - 16.45
PTS (Patto Trasversale per la Scienza) Meeting
 

Pre-Conference advanced course

Viral reservoir as obstacle to cure
 
Artistic contest RaccontART HIV - Incontro con le scuole finaliste
 

Pre-Conference advanced course

Ageing with HIV infection: new scenarios and new challenges
 

Pre-Conference advanced course

Prevention and treatment of sexually transmitted diseases (STDs)
 

Pre-Conference advanced course

HIV and chronic viral hepatitis: the strategic role of the nurse
17.00 - 20.45

Aula Magna

ICAR 2019 Opening Session

17.00 - 17.30: Introducing ICAR 2019
Welcome Addresses

17:30 - 17:50: RaccontART HIV contest Awards

17:50 - 18:50: The centrality of the person between care and culture

18:50 - 19:05: Il sorriso di Andrea

19:05 - 20:05: Keynote Lectures

20:05 - 20:30: ICAR-CROI Awards 2019 for young Italian HIV investigators

20:30 - 20:45: Closing Remarks

20.45 - 22.30

Cortile d'Onore dell'Università

ICAR 2019 Welcome Reception
  • Aula Magna
    13.00-16.00

    Special event

    PTS (Patto Trasversale per la Scienza) Meeting

    PTS (Patto Trasversale per la Scienza) Meeting

    16.00-16.45

    Con la sponsorizzazione non condizionante di:

    Towards cure programs in HIV and HBV

    There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected in 2017 globally. There is no cure for HIV infection but effective ARV drugs can control the virus and help prevent transmission. An estimated 257 million people are living with HBV infection around the world. Similarly, current HBV treatments suppress HBV viral replication but do not completely clear the virus. Today researchers are committed to develop innovative therapies to achieve functional cure for patients: the symposium will address the expectancies of the scientific community and the update of the ongoing projects in HIV and HBV cure research.

    Chairs: A. Gori, G. Tambussi

    16.00 - 16.05 Introduction
    A. Gori
    16.05 - 16.15 The expectations from the point of view of the clinician
    G.C. Marchetti
    16.15 - 16.35 The scientific efforts in cure programs
    B. Moldt
    16.35 - 16.45 Discussion on Symposium issues
    17.30-20.45

    ICAR 2019 Opening Session

    17.00 - 17.15: Introducing ICAR 2019
    Welcome Addresses

    17:30 - 17:50: RaccontART HIV contest Awards

    17:50 - 18:50: The centrality of the person between care and culture

    18:50 - 19:05: Il sorriso di Andrea

    19:05 - 20:05: Keynote Lectures

    20:05 - 20:30: ICAR-CROI Awards 2019 for young Italian HIV investigators

    20:30 - 20:45: Closing Remarks

    ICAR 2019 Opening Session

    17.00 - 17.30 Introducing ICAR 2019
    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini
    17.00 - 17.15 Introducing ICAR 2019
    17.15 - 17.30 Welcome Addresses: Magnifico Rettore, Università degli Studi di Milano
    E. Franzini
    17.30 - 17.50 RaccontART HIV contest Awards
    Chairs: M. Errico, M. Galli
    17.50 - 18.50 The centrality of the person between care and culture
    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini
    17.50 - 17.55 Introduction
    17.55 - 18.10 The commitment of the city of Milan
    P. Majorino, Assessore alle Politiche sociali e Cultura della salute, Comune di Milano
    Introduced by
    Maria Rosaria Iardino, Milano
    18.10 - 18.30 Lecture of his most reverend excellence, the Archbishop of Milan
    Monsignor M. Delpini, Arcivescovo metropolita di Milano
    18.30 - 18.50 The contemporaneity of Leonardo da Vinci
    F. Galli, Direttore del Museo Nazionale della Scienza e della Tecnica "Leonardo da Vinci"
    18.50 - 19.05 Il sorriso di Andrea
    Chair: R. Cauda, M. Zazzi
    19.05 - 20.05 Keynote Lectures
    Chairs: G. Ippolito, A. Lazzarin, F. von Schloesser
    19.05 - 19.15 Introduction
    G. Ippolito, A. Lazzarin
    19.15 - 19.40 Mauro Moroni Memorial Lecture "HIV Cure"
    S.G. Deeks
    19.40 - 19.45 Introduction
    F. von Schloesser
    19.45 - 20.05 The Fourth Decade in HIV: new challenges
    G.V. Calvino
    20.05 - 20.30 ICAR-CROI Awards 2019 for young Italian HIV investigators
    Chairs: G. Angarano, A. Antinori, G. Silvestri
    Selected Italian Investigators

    INI-resistance dynamics from 2007 to 2017 in Italian clinical isolates
    D. Armenia Tor Vergata University of Rome – MENTORS F. Ceccherini-Silberstein, M. Santoro

    GSS of NRTI-backbone predicts time to virological failure of INI-based regimens
    A. Borghetti Cattolica del Sacro Cuore University of Rome – MENTOR S. Di Giambenedetto

    Quantification of CD64: a predictive biomarker for progression to active tuberculosis
    C. Ceriani ASST Ovest Milanese, Legnano (MI) – MENTOR P. Clerici

    Subclinical tubular impairment is common in ART-treated HIV+ patients in Uganda
    C. Costa Amedeo di Savoia Hospital, Turin – MENTOR A. Calcagno

    Evolution and reversibility of renal function after switch from TDF to TAF regimens
    R. Gagliardini National Institute for Infectious Diseases “L. Spallanzani”, Rome – MENTOR A. Antinori

    Impact of HBCAB+ on advanced liver fibrosis development in HIV-HBV infected patients
    V. Malagnino Tor Vergata University of Rome – MENTOR L. Sarmati

    Metabolomic profiling of HIV patients with and without HIV-associated dementia
    A. Mastrangelo Vita-Salute San Raffaele University, Milan – MENTOR P. Cinque

    Extracellular vesicle–associated cytokines in HIV-infected human ex vivo tonsils
    V. Mercurio University of Milan – MENTORS M. Biasin, L. Margolis

    HCV late relapse in patients with directly acting antiviral–related SVR 12
    C. Minichini Luigi Vanvitelli, University of Naples – MENTOR N. Coppola

    Effectiveness of single- vs multiple-tablet regimens as 1st-line ART in ICONA cohort
    A. Mondi National Institute for Infectious Diseases “L. Spallanzani”, Rome – MENTOR A. Antinori

    Modulation of gut microbiota improves mucosal permeability in HIV+ patients
    C. Pinacchio Sapienza University of Rome – MENTOR G. d’Ettorre

    Interferon-free regimens improve renal function in patients with chronic Hepatitis C
    F. Portunato Luigi Vanvitelli, University of Naples – MENTOR N. Coppola

    Genotypic and phenotypic susceptibility to fostemsavir in multidrug-resistant HIV-1
    F. Saladini University of Siena – MENTOR M. Zazzi

    In vitro activity of DTG/BIC/E/CAB on first-generation INSTI-resistant HIV-1
    F. Saladini University of Siena – MENTOR M. Zazzi

    ERAP2 administration reduces in vitro PBMC susceptibility to HIV-1-infection
    I. Saulle University of Milan – MENTOR M. Biasin

    Time to undetectable viral load achievement after ART start and risk of mortality
    V. Spagnuolo Vita-Salute San Raffaele University, Milan – MENTOR A. Castagna

    Increased SAMHD1 correlates with ISGs in HIV-1–infected patients
    M. Statzu Sapienza University of Rome – MENTOR C. Scagnolari

    Alzheimer’s dementia cerebrospinal fluid biomarkers in HIV-positive patients on cART
    M. Trunfio University of Turin – MENTOR A. Calcagno

    Relapse of symptomatic CSF HIV escape upon previously optimized cART regimen changes
    F. Turrini IRCCS San Raffaele Hospital, Milan – MENTOR P. Cinque

    Low performance of the oraquick HCV rapid antibody test in HIV/HCV-infected people
    S. Vita S.M. Goretti Hospital, Latina – MENTOR M. Lichtner

    20.30 - 20.45 Closing Remarks
    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: G. Ippolito, A. Lazzarin, F. von Schloesser

    19.05 - 19.15 Introduction
    G. Ippolito, A. Lazzarin
    19.15 - 19.40 Mauro Moroni Memorial Lecture HIV Cure
    S.G. Deeks
    19.40 - 19.45 Introduction
    F. von Schloesser
    19.45 - 20.05 The Fourth Decade in HIV: new challenges
    G.V. Calvino
    17.00 - 17.15 ICAR 2019 Closing Remarks

    Closing Remarks

    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini

  • Aula 211
    13.30-16.00

    Pre-Conference advanced course

    Viral reservoir as obstacle to cure

    Pre-Conference advanced course

    Viral reservoir as obstacle to cure

    The persistence of the viral reservoir is still the main obstacle to the eradication of HIV infection. The availability of new high-sensitivity techniques of investigation has allowed to increase the ability to characterize the reservoir, but leaving open questions about the reliability of the methods and the clinical significance of generated data. The course aims to present the current status of technologies potential aimed at the qualitative and quantitative assessment of reservoir in the patient follow-up, and deepen the current therapeutic strategies to limit the extent of viral reservoir as the first approach to HIV cure. Attendees will be involved with a questionnaire to evaluate the perception of the usefulness of some diagnostic tests or clinical markers for the patient's routine follow-up. The results of the survey will be discussed at the end of the course.

    Chairs: F. Bai, F. Saladini

    13.30 - 14.00 Measuring the reservoir today
    M. Santoro
    14.00 - 14.30 Evolution of reservoir during the infection: immunological aspects
    A. Bandera
    14.30 - 15.00 Evolution of reservoir during the infection: virological aspects
    F. Ceccherini - Silberstein
    15.00 - 15.30 Antiretrovirals distribution in sanctuaries
    A. Calcagno
    15.30 - 16.00 Discussion of survey results and conclusions
  • Aula 201
    13.30-16.00

    Special event

    Artistic contest RaccontART HIV - Incontro con le scuole finaliste

    Artistic contest RaccontART HIV - Incontro con le scuole finaliste

  • Aula Malliani
    13.30-16.00

    Pre-Conference advanced course

    Ageing with HIV infection: new scenarios and new challenges

    Pre-Conference advanced course

    Ageing with HIV infection: new scenarios and new challenges

    By 2030, 70% of HIV-infected patients will be 50 years of age or older and one third of people living with HIV will have at least three age-related comorbidities. In light of this changing epidemiology, HIV providers must recognize and manage this new picture of the disease. In addition to multiple comorbidities, the ageing HIV population is at risk for geriatric syndromes, such as frailty, falls, delirium and functional impairment. It is therefore necessary to adopt a multidisciplinary approach to the patient and a proactive management of comorbidities. Nevertheless, in the elderly subject with HIV infection, the personalization of antiretroviral therapy, which must be based on an in-depth knowledge of the characteristics of antiretroviral drugs, drug interactions with concomitant therapy and patient's clinical characteristics, is even more important.

    Chairs: A. Mondi, V. Spagnuolo

      Epidemiological data
    13.30 - 14.00 Ageing with HIV: current and future size of an epidemic
    G. Madeddu
      Pathogenetic bases
    14.00 - 14.30 Immunosenescence and inflammaging: from basic research to clinic
    G. d'Ettorre
      Clinical aspects
    14.30 - 15.00 Diagnosis and screening of frailty in ageing with HIV Infection
    G. Guaraldi
    15.00 - 15.30 Diagnosis and screening of neurocognitive disease in HIV
    P.M. Cinque
    15.30 - 16.00 Managing polypharmacy in elderly patient
    C. Gervasoni
  • Aula Crociera
    13.30-16.00

    Pre-Conference advanced course

    Prevention and treatment of sexually transmitted diseases (STDs)

    Pre-Conference advanced course

    Prevention and treatment of sexually transmitted diseases (STDs)

    Sexually transmitted diseases (STDs) are infections that are passed from one person to another through sexual contact. Antibiotics can treat STDs caused by bacteria, yeast, or parasites; for this correct diagnosis and treatment are crucial. PrEP (pre-exposure prophylaxis) has been shown to reduce the risk of HIV infection in people who are at high risk by up to 92% when taken consistently. Italian regulatory agency approved use of PrEP. This course is focused on STDs diagnosis and treatment and on PrEP request and management in clinical practice.

    Chairs: A. Muscatello, S. Nozza, R. Rossotti

    13.30 - 13.50 The current management of sexually transmitted diseases
    M. Cusini
    13.50 - 14.10 The support of the laboratory in STDs early diagnosis
    M.A. Latino
    14.10 - 14.30 Indications and clinical implications of vaccinations against STDs
    M. Orso
    14.30 - 14.45 The role of counselor and cultural mediator in prevention
    G. Fracca
    14.45 - 15.00 The PrEP clinic in hospital
    R. Bellagamba
    15.00 - 15.15 The PrEP clinic in check points
    L. Badia
    15.15 - 16.00 Discussion on Course issues
  • Aula 113
    13.30-16.00

    Pre-Conference advanced course

    HIV and chronic viral hepatitis: the strategic role of the nurse

    Pre-Conference advanced course

    HIV and chronic viral hepatitis: the strategic role of the nurse

    The current management of HIV-HCV co-infected patient in the clinic today requires more than ever, due to the characteristics of complexity, a management based on close medical-nurse collaboration and team-based approach to the patient. We will therefore define the role of the nurse in relation to the patient's helping relationship with new disease response and support for adherence to therapy, knowledge of HIV and HCV drugs and the role of the nurse in clinical research.

    Chairs: A.M. Bigoloni, V. Picciotto, C. Uberti Foppa

    13.30 - 14.00 Communication of diagnosis and management of disease chronicity: the point of view of the patient and the operator
    C. Ruggieri
    14.00 - 14.30 New anti-HIV and HCV drugs: interactions and undesirable effects
    T. Angelini Zucchetti
    14.30 - 15.00 Health counseling and adherence to therapy
    V. Picciotto
    15.00 - 15.30 Role of the nurse in clinical trial
    D.F. Manara
    15.30 - 16.00 Discussion on Course issues
  • Cortile d'Onore dell'Università
    20.45-22.30 ICAR 2019 Welcome Reception

    ICAR 2019 Welcome Reception

 
Aula Magna
Aula 211
Aula 201
Aula Malliani
09.00 - 10.00

Aula Magna

Keynote Lectures
10.05 - 11.35
11.40 - 12.40
12.40 - 13.10
13.15 - 14.00
14.05 - 14.50
14.55 - 16.25
16.30 - 17.30
17.30 - 18.00

Andrea De Luca Symposium

Facing Resistance in 2019

Symposium

New options for treating opportunistic infections in immunocompromised host
 

Symposium

Critical issues in ART

Renato Dalle Nogare Symposium

Global Health: disease burden, migration and ageing

Oral Communications

Challenges in HCV elimination

Oral Communications

A Healthy Brain in People Living with HIV

Poster Discussion

Social Science and management of HIV beyond antiretroviral therapy

Poster Discussion

Clinical HIV and Epidemiology

Oral Communications

Targetting 90-90-90

Oral Communications

Immunological insights of HIV infection

Oral Communications

New insights in HIV pathogenesis

Oral Communications

Let's PrEP now: Italian experiences

Oral Communications

Cancers and bacterial infections
 
  • Aula Magna
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: A. Cossarizza, M. Galli, B. Suligoi

    09.00 - 09.30 Exploiting HIV for the gene therapy of inherited diseases and cancer
    L. Naldini
    09.30 - 10.00 Looking to a future management of HIV patients: key elements for transition
    A. Antinori
    10.05-11.35

    Andrea De Luca Symposium

    Facing Resistance in 2019

    Andrea De Luca Symposium

    Facing Resistance in 2019

    Back in 1996 drug resistance was a terrible occurrence and the few pharmaceutical options we had at that time were fading away with just some codon changes. Nowadays, the picture has dramatically changed and multiple therapeutic strategies have been developed combining antivirals, immunological therapies, and vaccines. Nevertheless, there is still an occasion to think globally about Drug Resistance, in the recent past with some fundamental mutations, with newer approaches, and with a deeper look into reservoirs.

    Chairs: M. Andreoni, B. Rossetti, M. Zazzi

    10.05 - 10.20 Global epidemiology of HIV resistance and clinical relevance
    C.F. Perno
    10.20 - 10.35 Remembering M184V
    S. Rusconi
    10.35 - 10.50 Overcoming resistance: the role of monoclonal antibodies
    N. Gianotti
    10.50 - 11.05 Drug resistance in sanctuary sites
    S. Bonora
    11.05 - 11.35 Discussion on Symposium issues
    11.40-13.10

    Symposium

    New options for treating opportunistic infections in immunocompromised host

    Symposium

    New options for treating opportunistic infections in immunocompromised host

    Advanced HIV patients have with significant frequency classical opportunistic infections but also healthcare-related infections caused by multiresistant bacteria or yeasts. In the recent years healthcare-related and opportunistic infections in HIV-negative population had triggered the need to expand the therapeutic armamentarium with new drugs, characterized by a broader spectrum of action and/or less toxicity and more convenience. The indication for these drugs and the new perspectives offered by the anti-infective drugs pipelines must be part of the cultural background of the clinician who takes care of HIV patients.

    Chairs: G. Carosi, R. Cauda, D.M. Cirillo

    11.40 - 11.55 Innovation in diagnosis and treatment of CMV infection
    L. Sarmati
    11.55 - 12.10 Difficult to treat bacterial infections and immunodeficiencies
    M. Venditti
    12.10 - 12.25 Fungal infections: latest in prevention and management
    P. Viale
    12.25 - 12.40 Facing Mycobacteria in 2019
    L. Codecasa
    12.40 - 13.10 Discussion on Symposium issues
    13.15-14.00

    Con il supporto di:

    2DR: from opportunity to change of paradigm

    PLHIV are aware of the potential long-term risks of current ART therapies that in any case allow a control of viremia and a normal life expectancy. Dolutegravir represented a breakthrough therapy in HIV, demonstrated by 5 studies of superiority and by the recognition of an innovative product by the Italian regulatory agency, offering PLWH valid therapeutic options. Thanks to the results obtained in triple therapies, dolutegravir was subsequently studied in robust 2-drug studies that allows to question the current twenty-year paradigm of the 3 drug regimens. Today, 2-Drug regimens have been proposed, ensuring the same efficacy and safety of a 3 drug regimen to reduce patient exposure to ARVs and potential associated toxicities since from naïve patient.

    Chair: A. d'Arminio Monforte

    13.15 - 13.30 The effectiveness of dolutegravir: From the three drugs regimen to the two drug regimen
    A. Antinori
    13.30 - 13.45 Dolutegravir: the importance of the high barrier to resistance
    M. Zazzi
    13.45 - 14.00 Discussion on Symposium issues
    14.55-16.25

    Symposium

    Critical issues in ART

    Symposium

    Critical issues in ART

    Despite the evident success of ART, with almost all patients attaining virological suppression, many issues remain only partially addressed. For instance, too many patients withdraw from treatment and can thus transmit HIV infection and adolescents that have been infected vertically must face HIV infection and its management in a very critical phase of their lives.  Furthermore, there are still some shadow areas about the long-term efficacy of two-drugs regimens, and, while the toxicity of new ART regimens is certainly lower from that of the old ones, new regimens may not be free from not yet well defined adverse effects.

    Chairs: G. Angarano, T. Bini, G. Di Perri

    14.55 - 15.10 Lost in follow-up
    E. Girardi
    15.10 - 15.25 Growing with ART
    V. Giacomet
    15.25 - 15.40 Toxicity: one step forward, one step back
    P. Bonfanti
    15.40 - 16.00 2DR - 3DR: two points of view
    S. Di Giambenedetto, S. Lo Caputo
    16.00 - 16.25 Discussion on Symposium issues
    16.30-18.00

    Renato Dalle Nogare Symposium

    Global Health: disease burden, migration and ageing

    Renato Dalle Nogare Symposium

    Global Health: disease burden, migration and ageing

    HIV, the virus that causes AIDS, is one of the world's most serious public health challenges. According to UNAIDS, there were approximately 36.9 million people worldwide living with HIV/AIDS in 2017. In 2017, 21.7 million people living with HIV (59%) were accessing antiretroviral therapy globally, an increase of 2.3 million since 2016 and up from 8 million in 2010. AIDS-related deaths have been reduced by more than 51% since the peak in 2004. This unprecedented global response to the AIDS pandemic can serve as a paradigm for the response to other global health threats. The aim of this symposium is to describe how AIDS invented Global Health.

    Chairs: S. Babudieri, C. Giaquinto, T.S. Prestileo

    16.30 - 16.45 The global answer to HIV: how to win the war
    S. Vella
    16.45 - 17.00 Ageing as global health challenge
    R. Bernabei
    17.00 - 17.15 Migrant as global health challenge
    C. Nicoara
    17.15 - 17.30 End TB globally
    M. Raviglione
    17.30 - 18.00 Discussion on Symposium issues
  • Aula 211
    10.05-11.35

    Oral Communications

    Challenges in HCV elimination

    Oral Communications

    Challenges in HCV elimination

    Chairs: N. Coppola, C. Ferrari, T.A. Santantonio

    10.05 - 10.20 Diagnosis and management of NASH/NAFLD
    L.V. Valenti
    11.40-13.10

    Oral Communications

    A Healthy Brain in People Living with HIV

    Oral Communications

    A Healthy Brain in People Living with HIV

    Chairs: A.M. Cattelan, G. Lapadula, R. Maserati

    13.15-14.45

    Poster Discussion

    Social Science and management of HIV beyond antiretroviral therapy

    Poster Discussion

    Social Science and management of HIV beyond antiretroviral therapy

    Chairs: A. Bignardi, B.M. Celesia

    14.55-16.25

    Poster Discussion

    Clinical HIV and Epidemiology

    Poster Discussion

    Clinical HIV and Epidemiology

    Chairs: A. De Maria, N. Petrosillo

    16.30-18.00

    Oral Communications

    Targetting 90-90-90

    Oral Communications

    Targetting 90-90-90

    Chairs: G. Mazzola, F. Mazzotta, A. Saracino

    16.30 - 16.45 Different HIV screening strategies and their possible impact on HIV epidemics
    G. Parruti
  • Aula 201
    10.05-11.35

    Oral Communications

    Immunological insights of HIV infection

    Oral Communications

    Immunological insights of HIV infection

    Chairs: M. Lichtner, G. Tambussi, C. Tincati

    11.40-13.10

    Oral Communications

    New insights in HIV pathogenesis

    Oral Communications

    New insights in HIV pathogenesis

    Chairs: D. Cattaneo, S. Parisi, G. Scarlatti

    13.15-14.00

    Con la sponsorizzazione non condizionante di:

    The last mile towards HCV elimination

    Synergy within institutions, clinicians and network systems has been the basis to develop integrated strategies for the management of chronic liver disease due to HCV infection. The challenge now is to screen and diagnose all in need of treatment. It means to identity and engage the critical mass of the many unaware of their condition or the difficult-to-reach high-risk populations, ensuring a wide-scale treatment. The high efficacy and the excellent safety of the new pangenotypic therapy show evidence of a reduced need for intensive treatment monitoring and simplify screening, diagnosis and care in few visits. An effective streamline approach that can make elimination of HCV in Italy by 2030 a feasible goal.

    Chairs: G.B. Gaeta, M. Puoti

    13.15 - 13.30 Strategies for HCV control beyond network models
    A. Craxì
    13.30 - 13.45 Test and treat approach: the next step to eradication
    N. Coppola
    13.45 - 14.00 Discussion on Symposium issues
    14.05-14.50

    Con la sponsorizzazione non condizionante di:

    Long-life individuality in caring for HIV

    Nowadays challenges in caring for HIV are both the management of long-term antiretroviral therapy and the unmet needs of every single HIV-positive patient. Today antiretroviral drugs are easy to take, powerful and well tolerated. HIV-positive patients require long-life treatments and maintaining durability and tolerability of antiretroviral regimen in association with other co-administered drugs for incoming comorbidities. The aim of the symposium is to examine how current antiretroviral agents may be better incorporated into management strategies in daily practice to benefit patients now and to preserve the future. This is the most important goal: taking into account increasing age of HIV population and concomitant diseases and therapies that are now the challenge for Infectivologists.

    Chair: M. Andreoni

    14.05 - 14.20 The challenge of focusing on the right patient
    C. Mussini
    14.20 - 14.35 Tolerability: the long-life issue
    S. Lo Caputo
    14.35 - 14.50 Tailored Daily Practice
    A. Di Biagio
    14.55-16.25

    Oral Communications

    Let's PrEP now: Italian experiences

    Oral Communications

    Let's PrEP now: Italian experiences

    Chairs: M. Errico, B. Marchini, L. Sighinolfi

    16.30-18.00

    Oral Communications

    Cancers and bacterial infections

    Oral Communications

    Cancers and bacterial infections

    Chairs: A. Chirianni, G. Guaraldi, S. Piconi

  • Aula Malliani
    11.40-12.40

    Con la sponsorizzazione non condizionante di:

    The revolution of rapid molecular diagnosis near patient

    The aim of the workshop is to illustrate the advantages of rapid molecular diagnosis in the virology field. Different healthcare professionals (HCP) will provide an explanation of the technology and the impact of tests in different setting such as hospitals or alternative sites.

    Discussants: M. Cernuschi, S. Mattioli

    11.40 - 12.00 The impact of molecular technology on HIV
    A. Gori
    12.00 - 12.20 The impact of molecular technology on HCV
    C.F. Perno
    12.20 - 12.40 Discussion on Expert Meeting issues
    12.45-13.45

    Con la sponsorizzazione non condizionante di:

    Moving forward to tailored approaches: real life & future in virology

    Treatment personalization, based on patients' features, is becoming in HIV and HCV increasingly important. Efficacy, extremely high tolerability, as well as low DDI are now crucial treatment imperatives. Starting from real world clinical evidences going through innovative new treatment options, personalization is essential to ensure patients' high QoL and treatment effectiveness.

    Chair: G. Rizzardini

    12.45 - 13.00 DAA in clinical real life
    L. Kondili
    13.00 - 13.15 Real world evidences: QD INSTI based strategies
    S. Di Giambenedetto
    13.15 - 13.30 HIV- 1 infection: time to drive safely
    A. Castagna
    13.30 - 13.45 Discussion on Expert Meeting issues
    14.00-15.00

    Con la sponsorizzazione non condizionante di:

    Recent advances in the management of Gram positive infections: the evolving role of long acting therapy

    Gram positive infections are a continuing challenge for clinicians: while classic pathogens still persist and evolve acquiring new mechanisms of resistance, new pathogens emerge with intrinsic multiple antibiotics resistance profiles, causing life-threatening infections as nosocomial pneumonia and intravascular device associated bloodstream infections. Not less important, the population at risk, i.e. elderly with multiple comorbidities or recipients of various foreign bodies, is increasing. New therapy options are required, with increased bactericidal activity and antibacterial spectrum that includes multiple resistant pathogens. Finally, oral or long acting agents might be critical in order to reduce hospital costs with outpatient therapy feasible even for serious infections as bone and joint infections or endocarditis. In recent years the antimicrobial armamentarium has been enriched by very long acting anti Gram positive agents approved for the therapy of ABSSI, as oritavancin and dalbavancin. In particular, pharmacokinetic profile and convenient single dosing make dalbavancin an interesting option for other serious Gram positive infections requiring prolonged treatment courses, for example bone infections, endocarditis and intravascular line associated infections. The aim of this workshop is to critically review all available experiences with long acting agents in order to provide an up-to-date of the actual and potential future role of this options for serious Gram positive infections.

    Chair: M. Tavio

    14.00 - 15.00 Recent advances in the management of Gram positive infections: the evolving role of long acting therapy
    S. Borrè, M. Venditti
    15.15-16.15
    16.30-17.30

    Con la sponsorizzazione non condizionante di:

    Hospital acquired and Gram negative-resistant pneumonia

    The objective of the meeting is to have a clear picture of the nosocomial pneumonia related burden and patient outcome and provide clinicians with updates on the management of MDR Gram negative infections in the hospital setting.

    Chair: G. Di Perri

    16.30 - 17.30 Hospital acquired and Gram negative-resistant pneumonia
    M. Bassetti
 
Aula Magna
Aula 211
Aula 201
Aula Malliani
09.00 - 10.00

Aula Magna

Keynote Lectures
10.05 - 10.30
10.30 - 11.30
11.40 - 12.25
12.30 - 13.10
13.15 - 14.00
14.05 - 15.35

Symposium

Getting to zero in HIV and HCV

Fernando Aiuti Symposium

New immune tools and targets towards an HIV cure

Oral Communications

New challenges of viral hepatitis

Oral Communications

ART and long-term safety issues

Oral Communications

From naive to highly treated subjects. Efficacy of cART

Oral Communications

Social and PLWHIV related issues

Oral Communications

Resistance. Is it still a problem?

Oral Communications

Changing HIV epidemiology

Poster Discussion

HIV co-morbidities

Poster Discussion

Virology, Immunology and Basic science
 

Poster Discussion

Viral Hepatitis

Poster Discussion

HIV therapy and management
15.40 - 16.45

Aula Magna

Round Table "U=U"
16.45 - 17.00

Aula Magna

ICAR 2019 Special Awards
17.00 - 17.15

Aula Magna

ICAR 2019 Closing remarks
  • Aula Magna
    09.00-10.00 Keynote Lectures

    Keynote Lectures

    Chairs: M. Cernuschi, M.U. Mondelli, M. Puoti

    09.00 - 09.30 Community-based interventions on chemsex among MSM
    J. Garrido
    09.30 - 10.00 New perspectives for medical treatment of Hepatocellular Carcinoma
    A. Craxì
    10.05-11.35

    Symposium

    Getting to zero in HIV and HCV

    Symposium

    Getting to zero in HIV and HCV

    Achievement of the ambitious HIV and HCV elimination targets is put at risk by the challenges encountered in reaching out to key populations. This session aims to highlight best practices and suggests how to overcome existing barriers and move forward to get to Zero.

    Chairs: M.L. Cosmaro, P. Pezzotti, C. Torti

    10.05 - 10.20 Ending HIV in England by 2030 - issues and actions
    N. Gill
    10.20 - 10.35 Getting to zero in Italian MSM
    G.M. Corbelli, M. Farinella
    10.35 - 10.50 Gender identity and sexual health issues
    M. Formisano
    10.50 - 11.05 Getting to zero in people using drugs
    A. Guidotti
    11.05 - 11.20 Fast Track in every city
    B. Audoin
    11.20 - 11.35 Discussion on Symposium issues
    11.40-12.25

    Con la sponsorizzazione di:

    The beauty of what is possible

    Evolution of antiretroviral therapy transformed the HIV from a fatal disease to a manageable chronic condition, moving forward the unmet medical needs. The meaning in the real word practice is that efficacy, tolerability and simplicity should be evaluated in a longer timeframe, as life lasting treatment. Since the therapy will be for a longer life, also QoL plays a relevant role so the Italian guidelines states that HRQoL should be measured at baseline and at each clinical evaluation becoming one of the primary goal of ART. How can this evaluation can be done in clinical practice? It's time to rethink the point of view by adding pts' lifestyle consideration on top of the clinical aspects.

    Chair: A. d'Arminio Monforte

    11.40 - 11.55 Evolving triple therapy - filling the unmet need
    S. Lo Caputo
    11.55 - 12.10 Patient Reported Outcomes (PROs) in the clinical practice - changing the point of view
    A. Cingolani
    12.10 - 12.25 Discussion on Symposium issues
    12.30-14.00

    Fernando Aiuti Symposium

    New immune tools and targets towards an HIV cure

    Fernando Aiuti Symposium

    New immune tools and targets towards an HIV cure

    As we are conveying our scientific efforts towards the achievement of a cure for HIV infection, different strategies are nowadays being investigated. During this symposium, the major pathways exploitable within strategies of functional cure will be reviewed, that include the role of different immune cells involved in both viral persistence and protective immunity in both peripheral blood and tissues, the detailed insight of protective immune responses may that be delivered via vaccination or monoclonal therapeutics, as well as the fine characterization of the immunologic consequences of HIV infection within the gut. the symposium will also review the latest findings in terms of vaccination strategies.

    Chairs: M. Clementi, C.M. Mastroianni, G. Silvestri

    12.30 - 12.45 Gut damage and dysfunction: any insight towards an HIV cure?
    G.C. Marchetti
    12.45 - 13.00 Broadly neutralizing antibodies in the prevention and treatment of HIV infection
    F. Klein
    13.00 - 13.15 HIV vaccines: how far are we from a cure?
    B. Mothe
    13.15 - 13.30 New cells in HIV persistence and immune control
    C. Agrati
    13.30 - 14.00 Discussion on Symposium issues
    14.05-15.35

    Oral Communications

    New challenges of viral hepatitis

    Oral Communications

    New challenges of viral hepatitis

    Chairs: V. Cento, M.A. Di Pietro, V. Svicher

    15.40-16.45 Round Table U=U

    Round Table

    U=U

    The message U=U is a dramatic change in the history of HIV/AIDS epidemics. This message is the final demonstration that treatment as prevention (TASP) works. It is not a case that recently CDC, HHI and several other National Agencies have launched a program to stop HIV epidemics in 10 years in USA just concentrating on these two variables. If the message has an intrinsic objective value in terms of public health, its subjective meaning for PLWHIV is even greater. It means that stigma (or a large part of it) has no more reason to exist and it means that PLWHIV have the right and possibility to regain a normal life of relationships overcoming self-induced stigma. All these aspects will be discussed in the round-table that will approach the message in a holistic way.

    Chair: M. Tavio

    Moderatore: G. D'Amico

    Partecipanti: A. Antinori, G.M. Corbelli, F. Dal Molin, F. Maggiolo, P. Mazzoli, C. Mussini, A. Nava, M. Oldrini, B. Richman, M. Stagnitta
    16.45-17.00 ICAR 2019 Special Awards

    ICAR 2019 Special Awards

    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini

      ICAR 2019 Scientific Committee Awards
    A. d'Arminio Monforte
      SIMIT Awards to Best Oral Communications for Young Researchers
    M. Galli
    17.00 - 17.15 ICAR 2019 Closing Remarks

    Closing Remarks

    Chairs: A. Castagna, A. d'Arminio Monforte, M. Puoti, G. Rizzardini

  • Aula 211
    10.05-11.35

    Oral Communications

    ART and long-term safety issues

    Oral Communications

    ART and long-term safety issues

    Chairs: A.F. Capetti, A. Matteelli, M.C. Moioli

    10.05 - 10.20 Lifestyle changes (stop smoking)
    G.V.L. De Socio
    11.40-13.10

    Oral Communications

    From naive to highly treated subjects. Efficacy of cART

    Oral Communications

    From naive to highly treated subjects. Efficacy of cART

    Chairs: L. Butini, M.S. Clerici, L. Sarmati

    13.15-14.00

    Con il supporto incondizionato di:

    HIV: same day treatment in real life

    The de-stigmatization of PHLWA and the process of normalization of HIV disease should not lead to the minimization of its relevance for both individuals and society. Behind the slogan "test and treat" lies this dualism: the virtuous promptness of care, the absolute protagonist of the virtuous mentioned path, should not be confused with the hasty beginning of a therapy that must be taken longlife. It is important that all the stakeholders discuss and find together the way to enhance the drive of T & T in the context of the high standards of care obtained in our country.

    Chair: A. Lazzarin

    Discussant: M.L. Cosmaro

    13.15 - 13.30 Same day treatment: the evidence
    G. Di Perri
    13.30 - 13.45 Same day treatment: the road map
    M. Andreoni
    13.45 - 14.00 Discussion on Symposium issues
    14.05-15.35

    Oral Communications

    Social and PLWHIV related issues

    Oral Communications

    Social and PLWHIV related issues

    Chairs: A. Cingolani, S. Mattioli, L.A.R. Rancilio

  • Aula 201
    10.05-11.35

    Oral Communications

    Resistance. Is it still a problem?

    Oral Communications

    Resistance. Is it still a problem?

    Chairs: G. Antonelli, G. Palù, G. Poli

    11.40-12.30

    Oral Communications

    Changing HIV epidemiology

    Oral Communications

    Changing HIV epidemiology

    Chairs: G. d'Ettorre, G. Nunnari

    12.30-14.00

    Poster Discussion

    HIV co-morbidities

    Poster Discussion

    HIV co-morbidities

    Chairs: M. Borderi, P. Maggi

    14.05-15.35

    Poster Discussion

    Virology, Immunology and Basic science

    Poster Discussion

    Virology, Immunology and Basic science

    Chairs: M.R. Capobianchi, F. Ceccherini - Silberstein

  • Aula Malliani
    10.30-11.30

    Con il supporto incondizionato di:

    Innovation vs novelty

    Although the significant advances in HIV therapy in recent years, many treatment-related needs persist. New medicines are needed for a broad range of patients to ensure continued improvements in efficacy as well as other important areas for people living with HIV and physicians, such as tolerability, safety, long-term toxicity, resistance, drug drug interactions and convenience. In addition, recent results with pre-exposure prophylaxis (PrEP) for the prevention of HIV infection warrant further exploration of new delivery technologies to give people at greatest risk of HIV infection a number of prevention methods from which to choose.

    Chair: M. Galli

    10.30 - 10.50 The relevance of innovation in medicine
    G. Apolone
    10.50 - 11.10 Innovation in mechanism of action
    A. Castagna
    11.10 - 11.30 Innovation in therapeutic strategy
    D. Ripamonti
    11.40-12.40

    Effects of vitamin D deficiency and respiratory infections' prevention in HIV population

    Hypovitaminosis D is a very common disorder, regarding both Western and developing countries. A growing amount of data over the last years have shown vitamin D deficiency to be high prevalent among HIV-positive subjects. In addition to "classic" risk factors, such as female sex, low dietary intake, dark skin pigmentation and low sun exposure, HIV-related factors, including immune activation and antiretroviral adverse effects, may affect vitamin D status. We report an interventional, non-randomized experience of OM-85 BV immunization in a group of 104 HIV-infected subjects presenting recurrent seasonal respiratory bacterial infections. We compared the number of respiratory events, the use of antibiotics and the cost related to antibiotics before (2005-2006) and after (2008-2011) the introduction of such intervention. Respiratory infections dropped in all groups but in subjects with recurrent otitis, leading to a reduction in the use of antibiotics. This is the first report of the effect of OM-85 BV in vivo in HIV-infected subjects.

    11.40 - 12.00 Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic
    M. Borderi
    12.00 - 12.20 Four years of immunization with OM-85 BV to prevent respiratory infections
    A.F. Capetti
    12.20 - 12.40 Discussion on Expert Meeting issues
    12.45-14.00

    Poster Discussion

    Viral Hepatitis

    Poster Discussion

    Viral Hepatitis

    Chairs: A. Cascio, V. Esposito

    14.05-15.35

    Poster Discussion

    HIV therapy and management

    Poster Discussion

    HIV therapy and management

    Chairs: P.M. Cinque, A. Di Biagio

Plenary session

Special events session

Pre-Conference courses session

Symposium session

Oral Communications session

Poster Discussion session

Sponsored session

×
Chiudi